Quantitative imaging of 2 nm monolayer-protected gold nanoparticle distributions in tissues using laser ablation inductively-coupled plasma mass spectrometry (LA-ICP-MS).
Quantitative imaging of 2 nm monolayer-protected gold nanoparticle distributions in tissues using laser ablation inductively-coupled plasma mass spectrometry (LA-ICP-MS).
复制标题
DOI：
10.1039/c6an00123h
复制
发表时间：
2016-04-21
期刊：
影响因子：
--
通讯作者：
Vachet RW
中科院分区：
文献类型：
--
作者：
Elci SG;Yan B;Kim ST;Saha K;Jiang Y;Klemmer GA;Moyano DF;Tonga GY;Rotello VM;Vachet RW
功能化金纳米粒子（AuNPs）具有独特的性质，使其成为重要的生物医学材料。然而，这些材料的最佳使用需要了解它们在体内的命运。在这里，我们描述了使用激光烧蚀电感耦合等离子体质谱（LA-ICP-MS）的图像的生物分布的金纳米粒子在小鼠组织中静脉注射金纳米粒子。我们首次证明了非常小的（~ 2 nm核心）单层保护的AuNP的分布可以在低十亿分之一范围内的浓度下在动物组织中成像。此外，LA-ICP-MS图像显示，注射的金纳米粒子上的单层涂层影响它们的分布，这表明金纳米粒子在体内保持完整，它们的表面化学影响它们如何与不同的器官相互作用。我们还表明，当选择适当的组织匀浆进行基质匹配时，可以生成金纳米颗粒的定量图像。总体而言，这些结果证明了LA-ICP-MS用于跟踪体内生物医学相关AuNP的命运的效用，促进了改进的基于AuNP的治疗剂的设计。
Functionalized gold nanoparticles (AuNPs) have unique properties that make them important biomedical materials. Optimal use of these materials, though, requires an understanding of their fate in vivo. Here we describe the use of laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS) to image the biodistributions of AuNPs in tissues from mice intravenously injected with AuNPs. We demonstrate for the first time that the distributions of very small (~ 2 nm core) monolayer-protected AuNPs can be imaged in animal tissues at concentrations in the low parts-per-billion range. Moreover, the LA-ICP-MS images reveal that the monolayer coatings on the injected AuNPs influence their distributions, suggesting that the AuNPs remain intact in vivo and their surface chemistry influences how they interact with different organs. We also demonstrate that quantitative images of the AuNPs can be generated when the appropriate tissue homogenates are chosen for matrix matching. Overall, these results demonstrate the utility of LA-ICP-MS for tracking the fate of biomedically-relevant AuNPs in vivo, facilitating the design of improved AuNP-based therapeutics.